Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05776316 · ClinicalTrials.gov registry record · NA

Harm Reduction Services

A NA study of Substance Abuse and Drug Use, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
3
Study locations

NCT05776316 is a NA study of Substance Abuse and Drug Use that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 200 participants, below the 5,256-participant average among 58 other Substance Abuse trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05776316, a NA study of Substance Abuse and Drug Use, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).

Interventions

  • BEHAVIORAL Integrated Harm Reduction Intervention (IHRI)

Study Locations (3)

New York

  • NYU Langone Health - New York
  • Nathan Kline Institute - Orangeburg

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-11-25
Est. Completion 2028-03-28
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT05776316

The ClinicalTrials.gov registry entry for NCT05776316 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,256-participant average among 58 other Substance Abuse trials with a reported enrollment target (96% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Substance Abuse appearing as the primary indexed condition, and to 1 intervention - of which Integrated Harm Reduction Intervention (IHRI) is the first listed.

NCT05776316 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05776316 about?

NCT05776316 is a clinical study titled "Harm Reduction Services". The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).

What is the current status of trial NCT05776316?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-11-25. Estimated completion is 2028-03-28.

What conditions does trial NCT05776316 study?

This clinical trial studies the following conditions: Substance Abuse, Drug Use, Mental Illness.

What interventions are being tested in trial NCT05776316?

The interventions under investigation include: Integrated Harm Reduction Intervention (IHRI) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05776316?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05776316 being conducted?

This trial has 3 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.